COMP <GO>
NCNA vs TRAW // EV/EBITDA & P/E VALUATION
NuCana plc (NASDAQ) VS. Traws Pharma Inc. (NASDAQ) • 15-METRIC TALLY: NCNA 1
— TRAW 1
■ METRIC PARITY
LAST: $1.04 (-3.26%) • MKT CAP: $4.3M
valuation
—
LAST: $0.30 (-16.34%) • MKT CAP: $4.6M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NCNA VS. TRAW)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NCNA | TRAW | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | -35.00% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | 68.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 180.00% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 3/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 40.3 | 25.8 | +14.49 | NCNA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.3M | $4.6M | -$297.4K | TRAW | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NCNA REV | TRAW REV | NCNA GROSS % | TRAW GROSS % | NCNA FCF | TRAW FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $2.8M | — | — | — | -$18.2M |
| FY 2024 | — | $226.0K | — | — | — | -$29.8M |
| FY 2023 | — | $226.0K | — | — | — | -$17.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NCNA // BETA —
TRAW // BETA —